<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXYMORPHONE HYDROCHLORIDE</span><br/>(ox-i-mor'fone)<br/><span class="topboxtradename">Numorphan<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) agonist</span>; <span class="classification">analgesic</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b> B  (D for prolonged use or high doses at term)<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL, 1.5 mg/mL injection; 5 mg suppositories</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally and pharmacologically related to morphine. Analgesic action of 1 mg is reportedly equivalent to that of 10 mg
         of morphine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces mild sedation and, unlike morphine, has little antitussive action. In equianalgesic doses, may have less antitussive
         effect and may cause less constipation than does morphine but causes more nausea, vomiting, and euphoria.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of moderate to severe pain, preoperative medication, obstetric analgesia, support of anesthesia, and relief of anxiety
         in patients with dyspnea associated with acute ventricular failure and pulmonary edema.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pulmonary edema resulting from chemical respiratory irritants. Safe use during pregnancy [category B (D for prolonged use
         and high doses)], lactation, or in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC/IM</span> 11.5 mg q46h prn <span class="rdroute">IV</span> 0.5 mg q46h <span class="rdroute">PR</span> 5 mg q46h prn<br/><br/><span class="indicationtitle">Analgesia during Labor</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 11.5 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give undiluted.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute in 5 mL of sterile water or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 0.5 mg over 25 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Protect drug from light. Store suppositories in refrigerator 2°15° C (36°59° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, euphoria.</span> <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness,</span> lightheadedness, sedation. <span class="typehead">Respiratory:</span> <span class="speceff-life">Respiratory depression</span> (see morphine), apnea, <span class="speceff-life">respiratory arrest</span>. <span class="typehead">Body as a Whole:</span> Sweating, coma, shock. <span class="typehead">CV:</span> <span class="speceff-life">Cardiac arrest</span>, circulatory depression. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> add to CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 510 min IV; 1015 min IM; 1530 min PR. <span class="typehead">Peak:</span> 11.5 h. <span class="typehead">Duration:</span> 36 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Eliminated in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor respiratory rate. Withhold drug and notify physician if rate falls below 12 breaths per minute.</li>
<li>Supervise ambulation and advise patient of possible light-headedness. Older adult and debilitated patients are most susceptible
            to CNS depressant effects of drug.
         </li>
<li>Evaluate patient's continued need for narcotic analgesic. Prolonged use can lead to dependence of morphine type.</li>
<li>Medication contains sulfite and may precipitate a hypersensitivity reaction in susceptible patient.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use caution when walking because of potential for injury from dizziness.</li>
<li>Do not to consume alcohol while taking oxymorphone.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>